US Patent

US10570202 — Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer

Method of Use · Assigned to Merck Sharp and Dohme LLC · Expires 2035-02-03 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of a combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer, particularly cancers that express PD-L1.

USPTO Abstract

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.

Drugs covered by this patent

Inlyta (Axitinib) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2844`	—	Inlyta
`U-2844`	—	Inlyta

Patent Metadata

Patent number: US10570202
Jurisdiction: US
Classification: Method of Use
Expires: 2035-02-03
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.